Medical therapy for XXXX : a review.

@entity1 @entity7856 @entity323 @entity1067 @entity10831 @entity2182
INTRODUCTION: @entity1067 (BPH) is a common disease that affects @entity1 as they age. Historically the treatment has been primarily surgical in nature, but over the past 25 years significant advances in medical therapy have been made, sparing some @entity1 from interventional procedures. MATERIALS AND METHODS: This article highlights the current state-of-the-art with respect to medical therapy for lower urinary tract symptoms secondary to BPH (BPH-LUTS) including a review of landmark studies and recent areas of research in the field. RESULTS: Alpha blockers are considered first line when treating BPH-LUTS in @entity1 with small prostates and @entity10831 inhibitors (5-ARIs) are recommended in @entity1 with large symptomatic prostates. While, @entity7856 ( @entity7856 ) inhibitors are the mainstay of @entity323 therapy, they also play a role in treating BPH-LUTS. If @entity1 have persistent irritative storage symptoms after first line BPH therapy then @entity2182 ( @entity2182 ) medications can be added or substituted. Combination therapies can be used to provide short term symptom relief with long term disease management. CONCLUSIONS: Medical therapy remains the main treatment option for @entity1 suffering from BPH-LUTS. Numerous medical options are available that can be tailored to meet the individual's needs depending on their personal and prostate characteristics. An algorithmic approach, as we have defined within this article, can be a helpful guide to this decision-making process.
